Alaunos Therapeutics Inc (TCRT) Smart Money Holdings (13F, Q2 2026)

TCRT ranks #7464 out of 37507 tracked stocks by institutional interest, inside the more closely watched half of our coverage.

TCRT is a disclosed holding of Ken Griffin (Citadel Advisors LLC), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

30 institutions disclose a position in TCRT, but none treat it as a major bet — even BlackRock, Inc., its most concentrated holder, allocates just 0.0% of its own portfolio to it.

BlackRock has trimmed its TCRT position for two straight quarters, cutting it by $20.7K while still holding $48.3K.

TCRT reported a net loss of $4.0M over the trailing twelve months.

• Not yet profitable — net loss of $4.0M over the trailing twelve months
• Revenue declined 50.0% year over year
• Net income declined year over year, from -$4.0M to -$4.0M
• Operating cash flow was negative, using $2.9M in cash
• Current ratio of 2.45x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.38x equity — within a conventional range